Lilly drug misses Phase III target

Share this article:

Eli Lilly's gastric cancer drug Cryamza failed to hit its primary Phase III liver cancer target.

The Indiana drugmaker announced Wednesday that although the drug did not show a statistically significant gain over placebo for overall survival, results indicated “meaningful improvements” in secondary measures including progression-free survival and overall response rate.

ISI analyst Mark Schoenebaum said in April that a hepatocellular cancer indication could be worth around $200 million in sales.

The drug has orphan status for hepatocellular cancer. Lilly is also exploring the drug's use in other cancers, including non-small cell lung cancer.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M inVISION